| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Proprietary safety intelligence creates dual value: faster therapeutic development and biodefense.
LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 9, 2025 / Lunai Bioworks Inc. (NASDAQ:RENB), an AI-powered drug discovery and biodefense company, today announced the launch of a transformer-based platform that embeds biological risk intelligence directly into large language model (LLM) pipelines. This breakthrough uses virtual chemical screening to identify novel compounds as being potentially toxic, expediting therapeutic discovery and development. Through its application, this platform also addresses a growing security concern, the misuse of generative AI in designing hazardous biological or chemical compounds.
With generative AI rapidly transforming healthcare and biotech, investors and regulators are increasingly focused on the dual-use challenge: the same algorithms that discover new medicines could also be exploited to create novel toxins. Lunai Bioworks' solution embeds a proprietary neurotoxicity intelligence layer into LLM workflows, ensuring safety while preserving innovation.
Posted In: RENB
